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patients and compare with native coronary disease.
Methods: 10,289 consecutive patients underwent PCI at a single centre (2003-2010),
922(8.9%) with ISR who presented with new/recurrent symptoms. Demographic data
were collected and in hospital MACE documented at discharge (table 1).All cause
mortality was obtained from the Office of National Statistics out to 5 years (mean 3.1
+/-1.8).
Results: Cardiac risk factors, prior CABG and non-Caucasian ethnicity were more
prevalent in the restenosis group (table 1). Presentations of ISR were: 60.4% stable
angina, 30.6% unstable angina/Non-ST elevation MI and 9% ST-elevation Myocardial
Infarction. All cause mortality out to 5 years was not significantly different between
the two groups (figure 1).
Demographic and outcome data (Table 1)
Values expressed as mean +/- SD or number (%)
Figure 1
Conclusion: In-stent restenosis presents as Acute Coronary Syndrome in 40% cases
and is not a benign clinical entity.
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Background: Drug-eluting stent (DES) implantation is an effective treatment of in-
stent restenosis (ISR). However, preliminary results indicate that drug-eluting balloons
(DEB) may be a valid alternative, particulary for recurrent ISR. We sought to evaluate
the safety, feasibility and clinical results of a new DEB for the treatment of bare-metal
stent and DES restenosis.
Methods: We enrolled 106 consecutive ISR (BMS= 43%, DES= 67%) patients. All
PCI were performed with paclitaxel-eluting (3 μg/mm2) balloons (Pantera Lux
Biotronik TM). Cross-over to DES after DEB was allowed for severe plaque prolapse,
flow-limiting dissection or abrupt closure. DAPT (ASA+Clopidogrel) was mantained
for at least 3 months. Clinical follow-up was scheduled at 3 and 9 months, while
angiografic evaluation was ischemia driven only.
Results: Clinical characteristics were as follows: mean age 67.7+9.5 yrs; 84% male;
diabetes 21%; previous myocardial infarction 23% and previous CABG 20%. In 72%
of patients, PCI was elective, whereas in 28% was performed for an acute coronary
syndrome.The index lesion was located in the LAD in 39%, LCx in 15%, RCA in 25%,
SVG in 2% and coronary branches in 16%. ISR length and narrowing were 13 + 8 mm
and 76 + 14%. By Mehran classification, ISR was 1A=0%, 1B=9.4%, 1C=47% and
1D=2.7%; type II=29%, type III=5.6% and type IV = 4.6%. In 19% of patients, DEB
was used for 2 or more DES ISR. A single (60±19 sec) DEB inflation was performed.
Mean DEB diameter, length and inflation pressure were 3.07±0.5 mm (DEB/vessel
ratio 1.18), 20.5±6 mm and 11.5±1.9 atm.
Acute and 6-month clinical and procedural results
Conclusion: This study suggests that DEB are an effective and safe treatment of ISR,
even in more complex DES restenosis. This strategy may be a valid therapeutic option
to avoid multiple stent in stent for recurrent ISR.
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Background: The role of drug-eluting stent (DES) therapy for restenosis within bare
metal stents is well established; however its place in the management of restenosis
within DES is less clearly defined. Furthermore, drug resistance at an individual patient
level may play an important role in restenosis following DES therapy.
Methods: We pooled data from ISAR-DESIRE and ISAR-DESIRE 2 randomized trials
and compared outcomes in patients treated with sirolimus-eluting stents (SES) for
restenosis within bare metal stents versus restenosis within SES, as well as outcomes
in patients treated with paclitaxel-eluting stents (PES) for restenosis within bare metal
stents versus restenosis within SES. The primary endpoints of interest were late loss
and target lesion revascularization (TLR).
Results: A total of 650 patients were included in the current analysis, 325 treated with
SES and 325 treated with PES. Angiographic follow-up was available in 87%. In SES-
treated patients, both late loss and target lesion revascularization were lower in patients
treated for bare metal stent restenosis compared with SES restenosis (late loss
0.21±0.59 mm versus 0.41±0.66 mm respectively, P=0.0066, see Figure; TLR 8.0%
vs. 15.6% respectively, P=0.05). Against this in PES-treated patients, late loss and
target lesion revascularization were similar for bare metal stent restenosis compared
with SES restenosis (late loss 0.48±0.59 mm versus 0.39±0.71 respectively, P=0.47,
see Figure; TLR 19.0% vs. 12.9% respectively, P=0.15).
Conclusion: The efficacy of SES but not of PES is reduced when used for treatment
of SES-restenosis as compared to BMS-restenosis. These findings support the
aetiological relevance of drug resistance in DES-restenosis.
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